Search Within

Tala Shekarkhand

Formats
  1. Meeting Abstract (32)
  2. Journal Article (6)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (40)
  2. Center for Hematologic Malignancies (39)
  3. Department of Medicine (39)
  4. Hematologic Malignancies Research (39)
  5. Myeloma (39)
  6. CTCR Scholars (38)

More Groups

People
  1. Alexander Lesokhin (39)
  2. Carlyn Rose Tan (38)
  3. Hani Hassoun (38)
  4. Malin Hultcrantz (38)
  5. Sham Mailankody (38)
  6. Urvi Shah (38)

More People

Years
  1. 2024 (20)
  2. 2023 (13)
  3. 2022 (3)
  4. 2021 (1)
  5. 2020 (2)
  6. 2019 (1)
Publications
  1. Blood (19)
  2. Clinical Lymphoma, Myeloma and Leukemia (12)
  3. Blood Advances (2)
  4. Blood Cancer Journal (2)
  5. Journal of Clinical Oncology (2)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Elsevier Inc. (12)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those of non-African ancestry
    Meeting Abstract

    Maclachlan, K.; Papadimitriou, M.; Blaney, P.; McPherson, A.; Chu, T.; Diamond, B.; Ziccheddu, B.; Shekarkhand, T.; Poos, A.; Brown, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save